Q-omics provides the consensus-scored ZMYND19P1 profile across patient tissues and cancer cell-line models. ZMYND19P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZMYND19P1 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, ZMYND19P1 RNA expression shows 15,549 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, BLCA, and THYM as cancer lineages where ZMYND19P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMYND19P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMYND19P1 survival associations across molecular data types. ZMYND19P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMYND19P1 RNA expression–survival associations across cancer types. High ZMYND19P1 expression shows unfavorable associations in UVM, CESC and KIRP, but favorable associations in BRCA, READ and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZMYND19P1 RNA expression.
This table summarizes ZMYND19P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZMYND19P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMYND19P1 shows lower tumor expression in THCA and higher tumor expression in BLCA, LUAD, HNSC and STAD. The BLCA box plot shows higher ZMYND19P1 RNA expression in tumor versus normal tissue (log2 FC = +0.143, t-test p = .037).
This table shows molecular features associated with ZMYND19P1 in patient tissues and cancer cell lines. In patient samples, ZMYND19P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
